Acquisition of KaLy-Cell: GBA Group expands European pharmaceutical network in France

September 5, 2022
Featured Image

Through the acquisition of the French com-pany KaLy-Cell SAS (KaLy-Cell), the GBA Group is expanding its European pharmaceutical network. This represents a significant mile-stone for the GBA Group in offering a com-prehensive portfolio of services across the development phases of new safe pharmaceu-ticals, as well as chemicals for cosmetic and plant protection applications, to both nation-al and international clients.
KaLy-Cell SAS was founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and is currently headquartered in Plobsheim. The company provides contract research services with hepatocytes from vari-ous species to optimize the discovery, devel-opment, and approval of pharmaceuticals, food additives, and agrochemicals. KaLy-Cell thus makes a significant contribution to rele-vant safety studies and enjoys an excellent reputation in the industry due to its prestig-ious clientele.